Enveric Biosciences, Inc. - ENVB
About Gravity Analytica
Recent News
- 03.31.2026 - Enveric Biosciences Secures New U.S. Patent for Its EVM301 Series of Drug Candidates
- 03.27.2026 - Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2025
- 03.18.2026 - Enveric Biosciences Announces Registration of Five Trademarks
- 03.09.2026 - Hope For Non-Hallucinogenic Neuroplastogens [Drug Discovery Online]
- 02.25.2026 - The Patent War That Wasn’t: How Enveric’s Legal Win Reframes the Neuroplastogen Race [Pharma Tech News]
- 02.25.2026 - Gilgamesh Withdraws Patent Fight Against Enveric After $1.2 Billion AbbVie Deal, CEO Says Key Drug Claims Now Uncontested [Benzinga]
- 02.25.2026 - AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy [Microdose]
- 02.25.2026 - Enveric Biosciences Announces Withdrawal of Petition Against Its Patent
- 02.24.2026 - What Enveric Biosciences’ EB-003 data reveal about separating benefit from hallucinations [Pharma Device News]
- 02.19.2026 - Beyond the Trip: Enveric’s EB-003 and the Next Phase of Psychedelic-Inspired Drug Design [Meditech Today]